tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
pmid:
Hersperger R et al. Preparation and immunosuppressive activity of 32-(O)-acylated and 32-(O)-thioacylated analogues of ascomycin. 1999 Bioorg. Med. Chem. Lett. pmid:10021934
Praghakaran K et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. 1999 J. Pediatr. Surg. pmid:10022154
Reynolds PD et al. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. 1999 J. Clin. Endocrinol. Metab. pmid:10022435
Powers JF et al. Discordant effects of rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells. 1999 Neurosci. Lett. pmid:10025577
Scholz C et al. R73A and H144Q mutants of the yeast mitochondrial cyclophilin Cpr3 exhibit a low prolyl isomerase activity in both peptide and protein-folding assays. 1999 FEBS Lett. pmid:10025965
Clemann N and Bechter R Effects of rapamycin and FK 506 on rat Sertoli cells in vitro. 1998 Adv. Exp. Med. Biol. pmid:10026935
Atta MG et al. Tyrosine kinase inhibitors and immunosuppressants perturb the myo-inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells. 1999 Kidney Int. pmid:10027932
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 1999 Transplantation pmid:10030287
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Johnson CE et al. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. 1999 Am J Health Syst Pharm pmid:10030533
Dolinski KJ and Heitman J Hmo1p, a high mobility group 1/2 homolog, genetically and physically interacts with the yeast FKBP12 prolyl isomerase. 1999 Genetics pmid:10049913
Regazzi MB et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. 1999 Ther Drug Monit pmid:10051048
Zucker K et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. 1999 Ther Drug Monit pmid:10051052
Chen HY et al. Prediction of tacrolimus blood levels by using the neural network with genetic algorithm in liver transplantation patients. 1999 Ther Drug Monit pmid:10051054
Yamaguchi Y et al. Peroxynitrite formation during rat hepatic allograft rejection. 1999 Hepatology pmid:10051479
Clardy J Borrowing to make ends meet. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10051553
Briesewitz R et al. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10051576
Chambraud B et al. Immunophilins, Refsum disease, and lupus nephritis: the peroxisomal enzyme phytanoyl-COA alpha-hydroxylase is a new FKBP-associated protein. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10051602
Maesaki S et al. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. 1998 J. Antimicrob. Chemother. pmid:10052898
Haas RJ et al. Non-Hodgkin lymphoma after heart-lung transplantation: response to chemotherapy. 1999 Med. Pediatr. Oncol. pmid:10064195
Mortola E et al. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. 1998 Vet. Res. Commun. pmid:10066129
Inui A et al. Food allergy and tacrolimus. 1999 J. Pediatr. Gastroenterol. Nutr. pmid:10067752
Herzig K and Johnson DW Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. 1999 Nephrol. Dial. Transplant. pmid:10069238
Tarumi K et al. CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. 1999 Transplantation pmid:10071020
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Kessler M et al. A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. 1999 Transplantation pmid:10071045
Jain AB et al. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. 1999 Liver Transpl Surg pmid:10071348
Jain AB et al. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. 1999 Liver Transpl Surg pmid:10071354
Mitsumoto Y et al. FK506 with portal decompression exerts beneficial effects following extended hepatectomy in dogs. 1999 Eur Surg Res pmid:10072610
Jain A et al. Immunosuppressive therapy. 1999 Surg. Clin. North Am. pmid:10073182
Reyes J and Mazariegos GV Pediatric transplantation. 1999 Surg. Clin. North Am. pmid:10073188
Sigalet DL et al. Effect of combined immunosuppressive drug therapy on small intestinal nutrient transport in the rat. 1999 Clin. Biochem. pmid:10074892
Trajković V et al. Cyclosporin A suppresses the induction of nitric oxide synthesis in interferon-gamma-treated L929 fibroblasts. 1999 Scand. J. Immunol. pmid:10075015
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Kaplan B et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. 1999 Transplantation pmid:10075604
Takada S et al. Effect of hepatocyte growth factor on tacrolimus-induced nephrotoxicity in spontaneously hypertensive rats. 1999 Transpl. Int. pmid:10080403
Kleindienst R et al. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis carinii infection in a liver transplant patient receiving tacrolimus. 1999 Clin Transplant pmid:10081638
Ghasemian SR et al. Tacrolimus vs Neoral in renal and renal/pancreas transplantation. 1999 Clin Transplant pmid:10081648
Scott JS et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? 1999 Feb-Mar Transplant. Proc. pmid:10083017
Meiser BM et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. 1999 Feb-Mar Transplant. Proc. pmid:10083018
Bennett WM Renal complications after heart transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083019
Reichenspurner H et al. Tacrolimus-based immunosuppressive protocols in lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083062
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Undre NA et al. Low systemic exposure to tacrolimus correlates with acute rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083114
Melk A et al. P-glycoprotein expression in patients before and after kidney transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083115
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. 1999 Feb-Mar Transplant. Proc. pmid:10083131
Lohmann R et al. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083151
Kato T et al. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083158
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Molmenti E et al. Noncompliance after pediatric liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083164
Rayes N et al. Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir--how effective is it? 1999 Feb-Mar Transplant. Proc. pmid:10083200
Fischer L et al. Hepatitis G virus infection in liver transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083208
Murase N et al. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. 1999 Feb-Mar Transplant. Proc. pmid:10083238
Schulz T et al. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. 1999 Feb-Mar Transplant. Proc. pmid:10083251
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Kandaswamy R et al. Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. 1999 Feb-Mar Transplant. Proc. pmid:10083254
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Rao AS et al. Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. 1999 Feb-Mar Transplant. Proc. pmid:10083302
Kaibori M et al. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. 1999 Feb-Mar Transplant. Proc. pmid:10083347
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Opelz G Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. 1999 Feb-Mar Transplant. Proc. pmid:10083513
Kokado Y et al. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083515
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Zanker B et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083521
Mohamed MA et al. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. 1999 Feb-Mar Transplant. Proc. pmid:10083523
Yamashita K et al. Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. 1999 Feb-Mar Transplant. Proc. pmid:10083526
Wu MS et al. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. 1999 Feb-Mar Transplant. Proc. pmid:10083527
Schorlemmer HU et al. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. 1999 Feb-Mar Transplant. Proc. pmid:10083529
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Hoshino Y et al. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. 1999 Feb-Mar Transplant. Proc. pmid:10083547
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. 1999 Feb-Mar Transplant. Proc. pmid:10083549
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Vieregge B et al. Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. 1999 Planta Med. pmid:10083851
Shapiro R Tacrolimus in pediatric renal transplantation: a review. 1998 Pediatr Transplant pmid:10084728
Atkison P et al. Small bowel transplantation in children. 1997 Pediatr Transplant pmid:10084770
Webber SA 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. 1997 Pediatr Transplant pmid:10084782
Yura H et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. 1999 J Control Release pmid:10084872
Trimbur GM et al. Cloning, sequencing, and nucleolar targeting of the basal-body-binding nucleolar protein BN46/51. 1999 J. Cell. Sci. pmid:10085251
Liang J et al. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. 1999 Acta Crystallogr. D Biol. Crystallogr. pmid:10089303
Crabtree GR Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. 1999 Cell pmid:10089876
Kimura T et al. N-glycosylation is involved in the sensitivity of Saccharomyces cerevisiae to HM-1 killer toxin secreted from Hansenula mrakii IFO 0895. 1999 Appl. Microbiol. Biotechnol. pmid:10091323
Nakahama H et al. Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. 1999 Nephron pmid:10095178
Kenyon NS et al. Islet transplantation: present and future perspectives. 1998 Diabetes Metab Rev pmid:10095999